In contrast, TLR agonists, specifically targeting TLR7, 8, and 9, have been successfully used as therapeutics for melanoma and basal cell carcinoma (BCC), functioning by recruiting dendritic cells and inducing T-cell responses. The gene discussed is TLR7; the disease is melanoma.